the ADBL report

Issue #112, February 2020

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on November 21, 2019. The Committee reviewed Manufacturer submissions for twenty (20) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of twenty-one (21) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-seven (27) Drug Products underwent Expedited Review for listing on the *ADBL* effective December 1, 2019, and ten (10) Drug Products underwent Expedited Review for listing on the *ADBL* effective February 1, 2020.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Product was reviewed by CDR and the Expert Committee and added to the *ADBL* effective December 1, 2019:

- **CYSTADROPS* ophthalmic solution** (cysteamine hydrochloride) (RRD) via Special Authorization (SA)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective February 1, 2020:

- **CRESEMBA* 100 mg capsule & 200 mg/vial injection** (isavuconazonium sulfate) (AVP) via Restricted Benefit/SA
- **SKYRIZI* 75 mg injection syringe** (risankizumab) (ABV) via SA
- **TRELEGY ELLIPTA* 100 mcg/62.5 mcg/25 mcg inhalation powder** (fluticasone furoate/ umeclidinium bromide/ vilanterol trifenatate) (GSK) via Step Therapy/SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (02/2020)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of a New IC Grouping, effective February 1, 2020:

- Fingolimod hydrochloride* **0.5 mg capsule** (MYP, PMS, SDZ, TEV) via SA

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective December 12, 2019:

- **ENBREL* 25 mg vial injection & 50 mg injection syringe for Plaque Psoriasis** (etanercept) (AMG)
- **HUMIRA* (40 mg/0.8 mL injection syringe) 40 mg/syringe injection syringe for Plaque Psoriasis, Crohn's Disease, Ankylosing Spondylitis, Psoriatic Arthritis & Rheumatoid Arthritis** (adalimumab) (ABV)
- **RITUXAN* 10 mg/mL injection for Rheumatoid Arthritis** (rituximab) (HLR)
- **STELARA* (0.5 mL vial or syringe) 45 mg injection vial or syringe & (1.0 mL syringe) 90 mg/syringe injection syringe for Plaque Psoriasis** (ustekinumab) (JAI)

The Special Authorization criteria for coverage for the following Drug Products have been revised effective February 1, 2020:

- **APTIOM* 200 mg, 400 mg, 600 mg & 800 mg tablets for Partial-Onset Seizures** (eslicarbazepine acetate) (SUN)
- **FYCOMPA* 2 mg, 4 mg, 6 mg, 8 mg, 10 mg & 12 mg tablets for Partial-Onset Seizures or Primary Generalized Tonic-Clonic Seizures** (perampanel) (EIS)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (02/2020)